28th January 2021
- 0 comments
Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to explore the effects of psychedelic agent psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare and debilitating headache condition.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.